Dyne Therapeutics (NASDAQ:DYN) Announces Quarterly Earnings Results

Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings data on Monday. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04, RTT News reports. During the same period in the prior year, the company posted ($1.05) earnings per share.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded up $0.12 during mid-day trading on Wednesday, reaching $18.49. The company’s stock had a trading volume of 318,367 shares, compared to its average volume of 2,039,235. The stock has a 50-day moving average of $18.18 and a two-hundred day moving average of $18.62. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The stock has a market capitalization of $3.06 billion, a P/E ratio of -5.73 and a beta of 1.08. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of recent research reports. Chardan Capital reissued a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. JPMorgan Chase & Co. dropped their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $24.00 price target on shares of Dyne Therapeutics in a research note on Wednesday. Finally, HC Wainwright decreased their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.21.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 83,219 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total value of $1,512,921.42. Following the transaction, the director directly owned 7,962 shares of the company’s stock, valued at $144,749.16. This trade represents a 91.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,552,911 shares of company stock valued at $29,694,469. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. Thrivent Financial for Lutherans acquired a new stake in shares of Dyne Therapeutics in the 2nd quarter worth $420,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Dyne Therapeutics in the third quarter valued at about $419,000. Fox Run Management L.L.C. acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $322,000. Virtus Investment Advisers LLC increased its position in Dyne Therapeutics by 75.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,806 shares of the company’s stock worth $270,000 after purchasing an additional 5,937 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $268,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.